BioCentury
ARTICLE | Company News

Lundbeck, Chelsea Therapeutics deal

June 30, 2014 7:00 AM UTC

H. Lundbeck completed its acquisition of Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a contingen...